MIST Milestone Pharmaceuticals Inc.

21.48
-0.21  -1%
Previous Close 21.69
Open 21.5
Price To Book 3.96
Market Cap 526,114,838
Shares 24,493,242
Volume 41,579
Short Ratio
Av. Daily Volume 27,056
Stock charts supplied by TradingView

NewsSee all news

  1. Canadian VC at $5.1B at 3Qs 2019, with historical record $6.5B within reach

    TORONTO, Nov. 27, 2019 /CNW/ - Canadian venture capital (VC) disbursements are continuing red-hot record-setting pace, completing 452 financings totalled $5.1billion (excluding Verafin deal1) in the first three quarters

  2. Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

    MONTREAL and CHARLOTTE, N.C., Nov. 14, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced that Joseph G. Oliveto, President and Chief Executive Officer, will present at the following

  3. Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update

    – NODE-301 topline data readout expected in mid-1H20 – – Richard Pasternak, M.D. appointed to the Company's Board of Directors – MONTREAL and CHARLOTTE, N.C., Nov. 13, 2019 /PRNewswire/ -- Milestone Pharmaceuticals

  4. Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT

    MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment

  5. Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT

    MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to be initiated in 2020.
Etripamil
Angina
Phase 2 trial to be initiated 2H 2019.
Etripamil
Atrial fibrillation
Phase 3 open label data due 1H 2021.
Etripamil - NODE-302
Paroxysmal supraventricular tachycardia (PSVT)
Phase 3 top-line data due around end of 1Q 2020.
Etripamil - NODE-301
Paroxysmal supraventricular tachycardia (PSVT)
Phase 3 open label commencement of dosing announced October 3, 2019.
Etripamil - NODE-303
Paroxysmal supraventricular tachycardia (PSVT)

Latest News

  1. Canadian VC at $5.1B at 3Qs 2019, with historical record $6.5B within reach

    TORONTO, Nov. 27, 2019 /CNW/ - Canadian venture capital (VC) disbursements are continuing red-hot record-setting pace, completing 452 financings totalled $5.1billion (excluding Verafin deal1) in the first three quarters

  2. Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

    MONTREAL and CHARLOTTE, N.C., Nov. 14, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced that Joseph G. Oliveto, President and Chief Executive Officer, will present at the following

  3. Milestone Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Corporate Update

    – NODE-301 topline data readout expected in mid-1H20 – – Richard Pasternak, M.D. appointed to the Company's Board of Directors – MONTREAL and CHARLOTTE, N.C., Nov. 13, 2019 /PRNewswire/ -- Milestone Pharmaceuticals

  4. Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT

    MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment

  5. Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT

    MONTREAL and CHARLOTTE, N.C., Oct. 3, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the

  6. Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development

    MONTREAL and CHARLOTTE, N.C., Sept. 10, 2019 /CNW/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the

  7. Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development

    MONTREAL and CHARLOTTE, N.C., Sept. 10, 2019 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the